Separate and Combined Extrapancreatic Effects of GIP and GLP-1

Inclusion Criteria: * Total pancreatectomy * Caucasians between 30-75 years of age * Blood haemoglobin \>7.0 mmol/l for males and \>6.5 mmol/l for females Exclusion Criteria: * Pancreatectomy within the last 3 months * Ongoing chemotherapy or chemotherapy within the last 3 months * Treatment with GLP-1 receptor agonists within the last 3 months * Renal impairment (estimated by estimated glomerular filtration rate (eGFR) \<60 ml/min/1.73 m2) and/or albuminuria * Calcium related disease, hypo-/hyperthyroidism * Known significant liver disease, plasma alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3 × normal value or INR (The international normalised ratio based on prothrombin time) outside the normal range * Severe arteriosclerotic heart disease or heart failure (New York Heart Association (NYHA) group III or IV) * Pregnancy and/or breastfeeding * Use of more than 14 units of alcohol per week or abuse of narcotics * Any condition that the investigator feels would interfere with trial participation